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In 1882 Robert Koch identiﬁed Mycobacterium tuberculosis as the causative agent of tuberculosis (TB), a disease as ancient as
humanity. Although there has been more than 125 years of scientiﬁc eﬀort aimed at understanding the disease, serious problems
in TB persistthatcontribute to theestimated 1/3ofthe worldpopulation infected with thispathogen. Nonetheless, during theﬁrst
decade of the 21st century, there were new advances in the ﬁght against TB. The development of high-throughput technologies
is one of the major contributors to this advance, because it allows for a global vision of the biological phenomenon. This paper
analyzes how transcriptomics are supporting the translation of basic research into therapies by resolving three key issues in the
ﬁghtagainstTB:(a)thediscoveryofbiomarkers,(b) theexplanationofthevariabilityofprotection conferred by BCGvaccination,
and (c) the development of new immunotherapeutic strategies to treat TB.
1.Introduction
The challenge of the World Health Organization Stop TB
Strategy (WHO-STOP TB) and the Global Plan to Stop TB
[1, 2] is to eradicate tuberculosis (TB) by 2050, while the
UnitedNationsMillennium DevelopmentGoalsaim tohalve
TBprevalenceanddeathsby2015,ascomparedtotheirlevels
in 1990. These are important objectives for public health
considering the high burden of the disease, with almost 4
deaths each minute [1]. Moreover, the WHO estimates that
90% of multidrug resistant tuberculosis (MDR-TB) cases
are not diagnosed and treated according to international
guidelines. Extensively drug-resistant cases of TB (XDR-TB)
have been reported in 59 countries since the ﬁrst description
of XDR-TB in 2006 [1].
Since the development of the Bacillus Calmette-Gu´ erin
vaccine (BCG) in 1921 and the discovery of the principal
anti-TB drugs between 1940 and 1960, essentially no new
vaccines or drugs speciﬁc for this infection have become
available on the market; nonetheless, the use of “-omics”
approaches to better understand the host-bacillus interac-
tion, pathogen biology, and host resistance/susceptibility has
provided a new impulse for the development of anti-
TB strategies. These high-throughput methodologies have
recently been applied to delineate the bacillus infective pro-
cess and to understand the molecular responses of diﬀerent
immune mechanisms. These methods will ultimately lead to
a more rational design of novel prophylactic and therapeutic
tools against TB.
Microarray technology has been demonstrated to be
an especially important tool in these studies and has been
applied by diﬀerent laboratories around the world that are
trying to identify speciﬁc molecules responsible for key
aspects of the disease. Microarray studies have evaluated
a myriad of elements of the bacillus and host during the
infection. Most studies have focused on identifying novel2 Clinical and Developmental Immunology
drug targets and analyzing the gene expression of the host
during the course of cell invasion and subsistence [3, 4]. A
considerable number of articles have attempted to identify
the genetic bases of diﬀerent grades of virulence among M.
tuberculosis strains [5, 6], as well as among M. bovis [7], that
c a u s eT Bi nb o v i n e sa n da l s oi nh u m a n s[ 8].
A number of studies have evaluated the response of
the innate immune cells that the pathogen confronts when
it invades the lungs. Special attention has been devoted
to macrophages [9] and also to the response of dendritic
cells to the infection [10, 11]. These studies underline
the importance of these cells as the main orchestrators of
t h ep r i m i n go ft h ea d a p t i v ei m m u n er e s p o n s e s ;i nT Bt h e
Th1 response is essential to eﬀectively clear the infection
[12]. These studies were performed with a variety of cell
sources (i.e., Diﬀerent cell lineages, bronchoalveolar cells,
and bone marrow-derived cells), microbe strains and culture
conditions [9–11, 13]. They indicated that several genes are
involved in the cell response to invasion from mycobacteria,
and some of them are possible targets for intervention
strategies against the bacillus. Although these studies are
important for understanding the close interaction between
the bacilli and the invaded cells, they produced highly
variable results [13]. This makes it diﬃcult to extrapolate the
results to the more complex situation in the lungs, where a
highly diverse set of cells are present when the mycobacteria
arrives and triggers the innate and adaptive arms of the
immune response in a multifaceted manner.
Moreover, as will be mentioned later, novel evidence
from the immune response during infection, vaccination,
and therapy indicates that a complex array of diﬀerent
players takes part in these processes and engages several
mechanisms to eﬀectively clear the infection. This means
that the immune response functions through the activation
of diﬀerent types of responses that act at various levels to
triggera well-balanced response, rather than the uniqueacti-
vation of the Th1 mediators. This contradicts the previous
perceptionofthe immune system that led to the ideathat the
quantity of the Th1 mediators could reﬂect the subversion of
the pathogen and correlate with the protection by vaccines,
and the response to therapeutic regimens [14, 15].
Taking into account the availability ofpublished material
on the immune response to TB, this review will focus on
the studies that used high-throughput technology, such as
microarrays, to examine three currently important issues in
the battle against TB: (1) the development of biomarkers
for TB and response to treatment, (2) elucidation of BCG
vaccine eﬃcacy/failure, and (3) the development of novel
therapeutic strategies against the infection by boosting the
host immune response.
2.Biomarkersof TB
We deﬁne biomarkers as molecular features that indicate
a deﬁned status of the host in relation to any process or
intervention. For TB, biomarkers for diﬀerent situations are
needed. These situations include protection by vaccination,
discrimination of latent and active disease to facilitate rapid
diagnosis, and treatment outcome or assess relapse risk
[16, 17]. Therefore, these biomarkers would be of enormous
v a l u et oe v a l u a t en e wc a n d i d a t ev a c c i n e s ,d r u g so ra n yo t h e r
interventionalstrategybyacceleratingtheirtranslation tothe
clinic [16, 17].
The power of transcriptomics to identify transcriptional
biomarkers was previously demonstrated in classical studies
on breast cancer, where, through the analysis of the gene
expression signatures of primary tumors, identiﬁcation of
a predictive outcome proﬁle was possible [18]. Along these
lines, Jacobsen et al. [19] studied the gene expression
signature of peripheral blood mononuclear cells (PBMCs)
of patients with active TB compared to infected (latent
TB) patients and nonsinfected healthy individuals. The
evaluation, which combined microarrays, real-time PCRs
and a linear discrimination analysis approach, allowed
the authors to identify a set of genes including Rab33A,
lactoferrin and CD64, that could diﬀerentiate between
these three groups of individuals. More importantly, the
diﬀerent gene expression patterns of PBMCs allowed for
discrimination between individuals with latent TB and
patients with active disease and also between patients with
recurrent disease and cured TB patients [20]. In this work,
the authors used microarray chips to test 50,000 gene
sequences, and after discriminatory computational-based
analysis, they claimed that they could diﬀerentiate the four
groups of individuals using a set of 9 genes (RIN3, LY6G6D,
TEX264, C14orf2, SOCS3,KIAA2013,ASNA1,ATP5G1, and
NOLA3).
Although no studies have been published, to our knowl-
edge, reporting the clinical validation of these biomarker
candidates, the studies mentioned above are important
because the rationale for the approach rests on the study
of PBMCs as a surrogate for lung tissue. These cells are
considered a complex sampling that better resemble the
environment at the site of the infection, as opposed to
the evaluation of one speciﬁc cell type. In our view, this
approach isappropriateas a starting pointfor further studies
of the host response during the course of the infection
and for distinguishing between good and poor responders
that are subjected to interventional strategies (vaccines and
therapies).
More recently, Berry et al., [21] reported the analysis of
the transcriptome of patients with latent TB and active TB
and compared themto healthy subjects. The identiﬁcation of
a393genesetenabletheauthorstoidentifyageneexpression
signature that diﬀerentiates between latent and active TB.
These results were conﬁrmed comparing the transcriptome
of patients of diﬀerent parts of the world demonstrating
the power of the strategy adopted. Since this patients were
included into the groups analyzed with no other criteria
than the clinical data in order to deﬁne them as patients
with active or latent TB, and that 10%–20% of the patients
classiﬁed as with latent TB were grouped into the active TB
groupbytheirgeneexpressionproﬁles,theauthorssuggested
that these patients could represent those who will develop
active disease in the future [21]. Although this assumption
needs to be conﬁrmed by a longitudinal analysis, this study
is of outstanding importance not only for giving support toClinical and Developmental Immunology 3
the notion that a transcriptomic approach for TB biomarker
development is feasible, but mainly because obtaining such
biomarkers seems to be a matter of time
3.Assessment ofBCG Vaccination
Efﬁcacy/Failure
Another important issue confounding the TB epidemic is
why BCG vaccination exhibits high variability in conferring
protection among diﬀerent populations. Although BCG is
the most commonly used vaccine in the world with more
than two billion doses administered to humans since its
development by Albert Calmette and Camile Gu´ erin almost
90 years ago, it only confers good protection against TB in
infants and not adults [22]. In several murine models, BCG
confers good protection against experimental challenge with
M. tuberculosis and therefore is commonly used as a “gold
standard” for comparing the performance of new vaccine
candidates. For this reason, several articles have described
the eﬀects of BCG immunization on the immune response
in diﬀerent experimental models and also in humans [23],
but the exact immunological mechanisms that leads to BCG
protection or to its failure remain poorly understood.
With regard to transcriptomic approaches, the study
of Behr et al. [24] is exceptional. These authors evaluated
BCG samples used in diﬀerent parts of the world using
DNA microarrays and found a surprisingly high variability
between these vaccine samples in speciﬁc genome regions
associated with virulence. This providedthe ﬁrst explanation
for the global divergence in BCG vaccination eﬀectiveness
from the microbial perspective; however, this phenomenon
might notonly bedueto bacillivariability. Itmay also bedue
to variability in the protection responses among individuals
[23]. This has been noted in other vaccination strategies and
treatments.
Understanding BCG failure or eﬃcacy is important
because it represents a way to discover the mechanisms
underlying protection, which could be useful in the for-
mulation of more eﬃcient vaccines. In this context, host
transcriptome analysisfollowing BCGvaccination represents
a valid approach due to the robustness of the results and
the large set of data obtained. Despite the importance of
such studies, only a few have been published describing the
transcriptome analysis in the context of BCG vaccination.
Mollenkopf et al. [25] compared the modulation of
gene expression of mice immunized with BCG to those
experimentally infected with M. tuberculosis.T h i ss t r a t e g y
was useful to identify genes speciﬁcally responsive to BCG
immunization. A major concern of this evaluation was
the use of intravenous inoculation of the vaccine rather
than subcutaneous injection, which is used in the classical
vaccination protocol of BCG; nevertheless, this study is
of great importance because it illustrated a rapid lung
transcriptome response after BCG immunization.
Aranday Cortes and coworkers [26] studied the lung
and spleen transcriptome response of vaccinated and un-
vaccinated mice. The data analysis allowed identifying
expression proﬁles that could be associated with vaccination
eﬃcacy. The mice from this study were intradermally vacci-
nated and infected with M. bovis, and the results conﬁrmed
and extended the data from the previous Mollenkopf study
[25]. Curiously, so far there have not been any published
studies of human samples showing high-throughput tran-
scriptome proﬁling following BCG immunization.
Data obtained using a more focused method, such as
qRT-PCR, to evaluate 16 immune system genes, showed
that groups of children vaccinated with diﬀerent strains
of BCG feature Th1 responses and Treg cells associated
genes. Moreover, the results showed that BCG vaccines
used in Brazil and Denmark induce a response that is
related to the Th1 response in the PBMCs from neonates,
while the response to Japan BCG vaccines is related to an
inﬂammatory proﬁle [27]. This study indicatesthe feasibility
of gene expression studies in human samples following
BCG vaccination. Moreover, this approach could be useful
to better understand the nonspeciﬁc, beneﬁcial eﬀects of
BCG vaccination in children, a question that remains widely
neglected but represents a potential public health problem
if BCG is replaced by the new sub-unit vaccines against TB
[28, 29].
4.Development of Novel TherapeuticStrategies
against TB
The emergence of XDR-TB represents a challenge for the
developmentofnew, eﬀectivedrugswith shorter regimens of
treatment [1]. The classical antibiotic research and develop-
ment includes investigation of novel susceptibility pathways
of the mycobacterium metabolism that could be used as
targetsforthesecompounds.Onceagain, transcriptome pro-
ﬁling could be useful to identify the diﬀerentially expressed
genes in mycobacterium strains susceptible or resistant to
antibiotics [30].
In parallel with these pharmacological studies, immun-
ostimulation of TB patients has been proposed as an impor-
tant element that helps improve the outcome of the disease
[31, 32]. Candidate approaches are under intensive eval-
uation as immunotherapeutic options such as M. vaccae
and a detoxiﬁed cellular fragment compost of M. tubercu-
losis named “RUTI”, both tested in clinical trials [33–35].
However, the data indicate the necessity of a more detailed
characterization of their mechanisms of action to improve
the results observed, in which transcriptomal evaluations
could be useful.
DNA-based vaccines constructed with an M. leprae
65kDa heat-shock protein (DNA-hsp65) and developed by
the team of one of us (CLS) represent a new strategy for
immune interventionagainst TB.DNA-hsp65immunization
has been applied successfully in diﬀerent experimental
models of TB. Initially tested as a new vaccine candidate, the
data collected since 1992 show that this vaccine stimulates
a strong Th1-speciﬁc immune response towards the hsp65
immune-dominant antigen [36, 37]. Stimulation with four
doses of DNA-hsp65 vaccine can be maintained by using
diﬀerent formulations of microspheres or liposomes or
prime-boost strategy reducing up to 16 times the amounts4 Clinical and Developmental Immunology
of DNA needed to maintain the protective eﬃcacy [38–40].
Moreover, because mycobacterial Hsp65 is one of the most
extensively studied antigens among the several components
oftheHSPfamily with regard totheirantitumoral properties
[41–43], we evaluated the eﬀects of treatment with hsp65
in a phase I clinical trial. Hsp65 intratumoral vaccination
resulted in no toxic eﬀects in head and neck squamous cell
carcinoma patients [44, 45].
In 1999, Lowrie and co-workers [46] showed that the
DNA-hsp65 vaccine could be applied eﬀectively to treat
active TB, thus becoming the ﬁrst DNA vaccination protocol
to display such properties against an intracellular pathogen.
Subsequent studies that demonstrated the advantages of
DNA-hsp65 to treat latent TB infection and MDR-TB [47,
48] indicated their importance as one of the most promising
molecules against TB [31, 49].
Although signiﬁcant progress has been made towards
a better understanding of the prophylactic mechanism
of DNA-based vaccines in driving the immune response,
systematic characterization of DNA immunotherapy was
not undertaken before the work developed by our research
group [50]. We reasoned that the elucidation of the molec-
ular events underlying cellular states that occur during
DNA-hsp65 immunotherapy in response to M. tuberculosis
infection could be evaluated by quantifying diﬀerential
gene expression using microarray hybridizations and qRT-
PCR.
The results showed that the eﬀects of DNA-hsp65 im-
munotherapy in mice with active TB could be characterized
by gene expression analysis. A high number of transcripts
that code for proteins associated with the immune system
made it possible to distinguish treated from nontreated
animals [50]. Functional analysis of this group of genes
suggested that DNA-hsp65 therapy inhibits Th2 cytokines
and regulates the intensity of inﬂammation through ﬁne
tuning of the expression of various genes, including those
that code for IFN-γ, IL-17, lymphotoxin-α,T N F - α,I L - 6 ,
TGF-β, iNOS, and Foxp3. In addition, the expression levels
of a large number of genes and expressed sequence tags
previously unrelated to DNA therapy were modulated.
A correlation between gene expression and histopatho-
logical lesions of the lungs validated the data [50]. Because
the eﬀects of DNA therapy were reﬂected in the modulation
of gene expression, the genes identiﬁed as diﬀerentially
expressed could be considered transcriptional biomarkers of
DNA-hsp65 immunotherapy against TB.
Thus, we combined the methods that involve character-
ization of the transcriptional signatures of lungs from mice
infected with M. tuberculosis and treated with Hsp65 as a
genetic vaccine along with microarray, qRT-PCR analysis
and ﬁnally correlation of the gene expression data with
the histopathological analysis of lungs. This was instru-
mental to obtain a better understanding of the mechanism
of DNA-based immunomodulation [50]. Furthermore, we
proposed the term “transcriptype” to characterize tran-
scriptome signatures that diﬀer among healthy individuals,




High-throughput transcriptome analysis using microarrays
is helping to identify biomarkers for TB, understand BCG
eﬃcacy/failure, and develop alternative treatments such as
DNA-based immunotherapy. Nevertheless, the relatively few
studiesinthisﬁeldreﬂectthestriking diﬃcultyinintegrating
thelarge amount of datageneratedandeﬀectivelytranslating
it to clinical use. One of the main reasons for this problem is
the lack of integrative tools that provide investigators a more
complete and understandable picture of the transcriptome
modulation; however, some integrated eﬀorts are being
conductedinthisarea. TheTuberculosisDatabase(TBDB)at
Stanford University and the Broad Institute [51, 52]p r o v i d e
a platform with information regarding the M. tuberculosis
genome,protein,andgeneexpressiondata.Theyalsocontain
information regarding other mycobacterium-related species,
as well as gene expression data from mouse and human
samples. Moreover, future expansion of this platform is
planned to generate tools that will be able to combine gene
expression from the immune system with other data.
Systems biology is a relatively recent discipline that aims
to combine, and therefore better understand, the high-
throughput sets of genomic, transcriptomic, and proteomic
data using bioinformatic tools. Recently, systems biology
studies analyzed integrative data to evaluate the eﬀectiveness
of the yellow fever vaccine YF-17D [53, 54]. This vaccine
represents the most successful prophylactic immunization
against an infectious disease due to its high eﬃcacy, safety,
and long-lasting protection that can reach 35 years [55].
Even though more than 540 million doses have been
administered to humans since its development in 1937, the
mechanisms underlying its eﬃcacy remained poorly deﬁned
until recently. Seminal studies combined data from human
gene expression signatures after YF-17D vaccination using
multiparameter ﬂow cytometry analysis for cell type or
cytokine evaluation and computational analysis [53, 54].
This strategy led to the identiﬁcation of key elements
of the innate and adaptive immune system that predict the
immunogenicity and eﬃcacy of YF-17D vaccination, thus
providing a new perspective to vaccinology [56] that could
be applied to the combat of other infections as TB.
6.ConcludingRemarks
The application of microarray technology has been demon-
strated in diﬀerent settings. Currently, with the evolu-
tion of novel computational analysis tools, the integration
and extraction of the vast information generated by this
technology are supporting new and exciting discoveries.
This systems biology approach is now being applied to
the development of novel diagnostics, vaccines and, drugs
against TB, as well as to other areas of TB research [57, 58].
In our opinion, some key issues from the “host point of
view” that could beneﬁt from these integrative tools are the
investigation of BCG vaccine eﬃcacy/failure, the determina-
tionoftheimportance ofBCGnonsspeciﬁc beneﬁcialeﬀects,Clinical and Developmental Immunology 5
and the discovery of TB biomarkers and the evaluation of
novel therapeutic strategies, such as immunotherapy and
chemotherapy.
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